A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma
- 522 Downloads
Hepatectomy is considered as the potentially curative treatment for hepatocellular carcinoma (HCC) and used in some selected Stage IIIA HCC, which include multiple tumors more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s) (UICC TNM staging system, sixth edition). Transcatheter arterial chemoembolization (TACE) was used in retrospective studies to improve the survival outcome of resected HCC. However, its beneficial effect on the survival outcomes of the Stage IIIA patients has not been evaluated. The present study is to evaluate if hepatectomy combining with adjuvant TACE for Stage IIIA HCC result in better long-term survival outcome when compared with hepatectomy alone.
From January 2001 to March 2004, we conducted a prospective randomized trial in patients with Stage IIIA HCC (NCT00652587), recruiting 115 Stage IIIA HCC patients to undergo hepatectomy with adjuvant TACE (HT arm) or to undergo hepatectomy alone (HA arm) in our cancer center. Survival outcomes of the two arms were analyzed.
The demographic data were well matched between the two arms. There were no significant differences in the morbidity and in-hospital mortality between the two arms of patients. The most significant toxicities associated with adjuvant TACE were nausea/vomiting (54.4%) and transient hepatic toxicity (elevation of aminotransferase, 52.6%). Although there was no significant difference in the rate of recurrence between the two arms (50/57 vs. 56/58, P = 0.094), HT arm seemed to have more proportion of single lesion of recurrent HCC (χ 2 = 3.719, P = 0.054) and more proportion of potential curative therapy for recurrence (χ 2 = 4.456, P = 0.035). Until the time of censor, 92 patients had died. The 1-, 3-, and 5-year overall survival rates and median overall survival for HT arm were 80.7, 33.3, 22.8% and 23.0 months, respectively. The corresponding overall survival rates and median overall survival for HA arm were 56.5, 19.4, 17.5% and 14.0 months, respectively. The difference was significant (stratified log-rank test, P = 0.048). The 1-, 3-, and 5-year disease-free survival rates and median disease-free survival for HT arm were 29.7, 9.3, 9.3% and 6.0 months, respectively; correspondingly, for HA arm were 14.0, 3.5, 1.7% and 4.0 months, respectively (stratified log-rank test, P = 0.004).
For Stage IIIA HCC, hepatectomy with adjuvant TACE efficaciously and safely improved survival outcomes when compared with hepatectomy alone.
KeywordsLiver neoplasms Hepatectomy Chemoembolization Survival rate
This study was supported in part by the grant of Science-Techonolgy Project Foundation of Guangdong Province, China, 2006 (No. 2006B36002013).
Conflict of interest statement
- Guo RP, Chen MS, Lin XJ et al (2000) Significance of removing portal vein thrombus and TACE in improving outcome of resection for primary liver cancer with portal vein tumor thrombus. Chin J Hepatobiliary Surg 6:374–376Google Scholar
- Ikeda K, Arase Y, Saitoh S et al (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228–232. doi: 10.1053/jhep.2000.9409 CrossRefPubMedGoogle Scholar
- International Union Against Cancer (UICC) (2002) In: Sobin LH, Wittekind C (eds) TNM classification of malignant tumors, 6th edn. Wiley, New York, pp 81–83Google Scholar
- Liver Cancer Study Group of Japan (1990) Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 211:277–287Google Scholar
- Ono T, Yamanoi A, Nazmy El Assal O et al (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91:2378–2385. doi: 10.1002/1097-0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2 CrossRefPubMedGoogle Scholar
- Stefanini GF, Amorati P, Biselli M et al (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience. Cancer 75:2427–2434. doi: 10.1002/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J CrossRefPubMedGoogle Scholar
- Ueno K, Miyazono N, Inoue H et al (2000) Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 88:1574–1581. doi: 10.1002/(SICI)1097-0142(20000401)88:7<1574::AID-CNCR11>3.0.CO;2-8 CrossRefPubMedGoogle Scholar